FDA approves new drug for worse retinal conditions
Quick Read
Vabysmo is the first and only FDA-approved injectable eye medicine that improved and maintained vision with treatments from one to four months.
Swiss pharmaceutical company, Roche on Monday said the Food and Drug Administration (FDA) has approved a drug named Vabysmo for the treatment of conditions that can result in loss of vision.
The drug targets neovascular age-related macular degeneration and diabetic macular oedema; the two conditions are leading causes of vision loss worldwide.
The company noted that Vabysmo was the first and only FDA-approved injectable eye medicine that improved and maintained vision with treatments from one to four months, apart from the first year following four initial monthly doses.
“Vabysmo provides a new approach to treating vision-threatening retinal conditions through a mechanism of action that targets two pathways simultaneously.
“Vabysmo will be available in the United States in the coming weeks,” said Levi Garraway, Roche’s chief medical officer.
dpa/NAN
Comments